An EGLN1 mutation may regulate hypoxic response in cyanotic congenital heart disease through the PHD2/HIF-1A pathway

Area of Science:

• Cardiovascular Genetics
• Molecular Biology
• Hypoxia Research

Background:

• Cyanotic congenital heart disease (CCHD) involves severe heart malformations and right-to-left shunts, leading to chronic hypoxia and poor prognosis.
• The prolyl-4-hydroxylase 2 (PHD2, encoded by EGLN1)/hypoxia-inducible factor-1A (HIF-1A) pathway is crucial for regulating cellular responses to hypoxia.
• Understanding genetic factors influencing hypoxic response in CCHD is vital for improving patient outcomes.

Purpose of the Study:

• To investigate the association between single nucleotide polymorphisms (SNPs) in the EGLN1 gene and the hypoxic response in patients with CCHD.
• To elucidate the molecular mechanisms underlying the observed associations, particularly concerning the PHD2/HIF-1A pathway.

Main Methods:

• Genotyping of EGLN1 SNPs in a cohort of CCHD patients.
• Clinical data analysis to correlate genotypes with hypoxia incidence and collateral vessel formation.
• In vitro experiments to assess the functional impact of EGLN1 variants on gene expression (HIF-1A, VEGF, EPO) under hypoxic conditions.

Main Results:

• A specific missense variant, EGLN1 c.380G>C (rs1209790), was identified in 46 out of 126 CCHD patients.
• Patients with the c.380G>C variant exhibited lower hypoxia incidence and increased collateral vessel formation compared to wild-type counterparts (P < 0.05).
• In vitro studies confirmed that the EGLN1 mutation reduced EGLN1 expression, leading to elevated HIF-1A, VEGF, and EPO levels during hypoxia.

Conclusions:

• The EGLN1 c.380G>C mutation enhances the hypoxic response in CCHD patients, likely by modulating the PHD2/HIF-1A pathway.
• This genetic variation may offer a protective mechanism against severe hypoxia in CCHD.
• Further research is warranted to explore the impact of the EGLN1 c.380G>C mutation on CCHD prognosis and clinical management.